The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
暂无分享,去创建一个
H. G. van der Poel | K. Haustermans | M. Graefen | A. Briganti | R. Karnes | B. Tombal | F. Claessens | F. Chun | M. Spahn | J. Walz | A. Laenen | M. Albersen | P. Gontero* | W. Everaerts | C. Gratzke | S. Joniau | P. Bastian | H. Van Poppel | G. De Meerleer | T. Van den Broeck | A. Bossi | B. Kneitz | P. Chłosta | G. Marchioro | L. Tosco | R. Salas | P. Gontero
[1] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[2] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[3] A. Haese*,et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. , 2015, The Journal of urology.
[4] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[5] F. Montorsi,et al. Early radiotherapy after radical prostatectomy improves cancer‐specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria , 2015, International journal of urology : official journal of the Japanese Urological Association.
[6] M. Terris,et al. The impact of pathologic staging on the long‐term oncologic outcomes of patients with clinically high‐risk prostate cancer , 2014, Cancer.
[7] M. Terris,et al. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. , 2014, European urology.
[8] David C. Miller,et al. Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .
[9] W. Isaacs,et al. Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.
[10] N. Murray,et al. Secondary Circulating Prostate Cells Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease , 2013, TheScientificWorldJournal.
[11] L. Collette,et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.
[12] M. Cooperberg,et al. The CAPRA‐S score , 2011, Cancer.
[13] Robert A. Weinberg,et al. Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.
[14] Mei-Jie Zhang,et al. Marginal Models for Clustered Time‐to‐Event Data with Competing Risks Using Pseudovalues , 2011, Biometrics.
[15] Ewout W. Steyerberg,et al. Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.
[16] N. Willich,et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Chin,et al. UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL , 2008 .
[18] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[19] E. Bergstralh,et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.
[20] John P Klein,et al. Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence Function , 2005, Biometrics.